BUSINESS
Biocon confident of meeting $200-million revenue guidance target for biologics segment
“We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.
BUSINESS
Dr Reddy’s says focusing on resolving regulatory issues, cost optimisation
“Looking ahead, our priority will be to resolve pending regulatory issues, and continue to work on execution and cost structures that will enable affordable medicines for more patients,” GV Prasad, Co-chairman and CEO of Dr Reddy’s said.
BUSINESS
Re-audit of Duvvada unit: Why an all clear holds importance for Dr Reddy’s
A portion of complex abbreviated new drug applications is filed from this facility
BUSINESS
Modi govt destroying institutions like CBI: Andhra Pradesh CM Chandrababu Naidu
The TDP supremo evaded questions on efforts to bring the Opposition together
BUSINESS
Patients with faulty J&J hip implants say no word from govt so far on compensation
Although J&J has been criticized for failing to pay any compensation for its faulty hip implant in India, there are currently no legal provisions to provide compensation to affected patients
BUSINESS
Weekly blog: More questions, no definitive answers on source of polio vaccine contamination
Bio Farma told Moneycontrol that it had conducted an internal investigation of the facility and that testing of retained samples of all bulks shipped to Bio-Med had found no of presence of a type 2 polio virus
BUSINESS
Biocon inches closer for Europe approval of biosimilar Trastuzumab
Trastuzumab, the biosimilar version of Swiss drug maker Roche’s Herceptin had brand sales of $1.9 billion in Europe for the 12 months ended July 31, according to IQVIA.
BUSINESS
Lupin gets 5 observations from USFDA for Pithampur Unit-3 facility
The pre-approval inspection (PAI) was triggered after the company filed Tiotropium dry powder inhalation (DPI) abbreivated new drug application (ANDA).
BUSINESS
Will Dr Reddy's biosimilar programme for developed markets see traction?
The drug maker's partner Fresenius Kabi has completed clinical trial for Pegfilgrastim and announced that the drug has met primary end point in two pivotal clinical studies.
BUSINESS
Bio-Med polio episode underlines the story of India's famed vaccine industry losing prowess
India, once the manufacturing powerhouse of vaccines, is seeing a slow decline. India’s vaccines exports dropped 4 percent to $653.40 million in FY18
BUSINESS
Sacked IL&FS MD blames LIC, macro factors for mess, denies fund diversion charges
Sankaran asked NCLT to appoint an independent foreign agency without conflict of interest, rather than a local one, to investigate the company's affairs
BUSINESS
Piramal considers $1-billion pharma services business sale: Reports
But analysts say pharma services constitute 6-7 percent of Piramal's revenues and is a drag on overall pharma business.
BUSINESS
E-pharmacy definition outdated, changes should be made to attract FDI, says IAMAI
The Union Health Ministry recently released draft rules for e-pharmacies to regulate online sale of medicines across the country and provide patients accessibility to genuine drugs.
BUSINESS
Dr Reddy's on cost cutting spree to counter US pricing pressures
The company has been selling manufacturing plants, optimizing product portfolios, removing layers of management that it considers wasteful and taking re-look at R&D investments.
BUSINESS
Biocon-Mylan may benefit from Merck's exit of insulin glargine in US
Insulin glargine is a biosimilar of French drug maker Sanofi's top selling Lantus that had sales of around $5.3 billion in 2017, of which US constitutes around 55 percent.
BUSINESS
Why India needs a comprehensive policy on OTC drugs
Many would be surprised that the term OTC doesn't exist as per Indian law. Neither the Drugs & Cosmetics Act, 1940 nor the Drugs & Cosmetics Rules, 1945 define OTC
BUSINESS
Natco's partner Mylan prevails over Teva in Copaxone patent litigation
Natco's partner Mylan went ahead and launched Copaxone 40 mg “at-risk” in US in October last year even as the patent litigation is still on. Any setbacks in the patent litigation could have led to significant damages among other remedies for both the companies.
BUSINESS
USFDA releases guidance to help generic drug makers copy complex ones
"These draft guidances are aimed at ensuring that we provide as much scientific and regulatory clarity as possible with respect to complex generic drugs," US FDA Commissioner Scott Gottlieb in a statement.
BUSINESS
UP govt woos pharma cos, private healthcare firms with mega parks, public private partnership model
The state has received an investment commitment of about Rs 5,000-6,000 crore from domestic and multinational pharma companies,
BUSINESS
Indian pharma market grows 9.7% in Q2FY19 on uptake across therapy segments
IPM grew close to 10 percent in first half of this financial year FY19, returning to the 10 percent growth of FY17.
BUSINESS
LifeCell rejigs biz after Centre restricts commercial stem cell banking
LifeCell had moved from a private stem cell bank to a community bank unlike a private bank that is exclusively meant for the use of the baby or its immediate family members
BUSINESS
How Indian stent maker SMT is taking the battle to MNC shores
The study called 'Talent trial' was one of the largest ever clinical train conducted by an Indian company overseas to test a medical device
BUSINESS
Gujarat pharma industry says business as usual, but seeks govt action against attacks on migrant workers
Gujarat is the manufacturing hub for pharmaceuticals, housing over 3,300 manufacturing units, including some of the large drug makers such as Sun Pharma, Torrent Pharmaceuticals, Cadila Healthcare and Intas, contributing around 28 percent of India's pharmaceutical exports.
BUSINESS
Why India can't drop the ball on polio-free status
Polio eradication is one of very few success stories that India can boast off, after small pox elimination.
